Anika Therapeutics, Inc. (ANIK) is a Healthcare stock trading at $14.39 (as of 2026-06-18), with a market capitalization of $191.73M and a trailing P/E of -18.6. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Anika Therapeutics, Inc. develops, manufactures, and commercializes products based on a hyaluronic acid technology platform for early intervention orthopedic care. Its osteoarthritis pain management products include Monovisc, Orthovisc, Cingal, and Hyvisc, along with joint preservation, soft-tissue repair, regenerative and other HA-based applications, sold in the United States, Europe, and internationally.